Emergent BioSolutions Inc. has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted).
The contract modification aims to supply the two-dose anthrax vaccine for post-exposure prophylaxis use.
Deliveries are expected to begin this calendar year and be completed by March 2026.
Contract Modification
Emergent BioSolutions Inc. secured a $30 million contract modification to supply CYFENDUS® for post-exposure prophylaxis against anthrax.
U.S. Government Engagement
The contract underscores Emergent's shared goal with the U.S. government to safeguard civilian populations against anthrax threats.
Anthrax Vaccine Approval
CYFENDUS® was approved by the FDA as a two-dose anthrax vaccine in July 2023 for individuals aged 18 to 65 for post-exposure prophylaxis.
- Anthrax is classified as a Tier 1 biological threat, emphasizing the importance of vaccines like CYFENDUS® in bioterrorist incident preparedness.
- The contract modification signifies the U.S. government's commitment to national security priorities and the availability of medical countermeasures against anthrax threats.
The awarded contract modification highlights the critical role of Emergent BioSolutions Inc. in supplying anthrax vaccines for national security preparedness. The ongoing engagement with the U.S. government underscores the importance of CYFENDUS® in protecting against anthrax threats.